According to clinical trial data published online by the journal Current Pharmaceutical Design, oral administration of the non-psychotropic cannabis plant constituent cannabidiol (CBD) is safe and well tolerated in humans.
The physiological and behavioral effects of CBD and THC versus placebo were assessed by investigators at Kings College in London in 16 healthy volunteers in a randomized, double-blind, crossover trial.
The study “Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers” appeared online in Current Pharmaceutical Design.
It was reported by the investigators that oral administration of THC (10 mg) was linked with different physiological and behavioral effects like increased heart rate and sedation whereas the oral administration of 600 mg of CBD was not. It was concluded, “There were no differences between CBD and placebo on any symptomatic, physiological variable. … In healthy volunteers, THC has marked acute behavioral and physiological effects, whereas CBD has proven to be safe and well tolerated.”
The non-psychotropic cannabis plant constituent cannabidiol (CBD) was termed safe, non-toxic, and well tolerated by a previous review of the use of CBD in human subjects, published in the scientific journal Current Drug Safety last year.